Shenzhen New Industries Biomedical Engineering Co., Ltd. logo

Shenzhen New Industries Biomedical Engineering Co., Ltd. (300832)

Market Closed
10 Aug, 06:57
XSHE XSHE
¥
49. 02
+0.73
+1.5117%
¥
45.79B Market Cap
- P/E Ratio
5.2% Div Yield
11.51M Volume
- Eps
¥ 48.29
Previous Close
Add Transaction
Day Range
46.5 50.5
Year Range
37.5 71.51
Want to track 300832 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

300832 closed today higher at ¥49.02, an increase of 1.5117% from yesterday's close, completing a monthly increase of 16.9928% or ¥7.12. Over the past 12 months, 300832 stock lost -13.2696%.
300832 pays dividends to its shareholders, with the most recent payment made on May 27, 2026. The next estimated payment will be in In 9 months on May 27, 2027 for a total of ¥1.2.
The last earnings report, released on Apr 28, 2026, missed the consensus estimates by -0.566%. On average, the company has fell short of earnings expectations by -0.242%, based on the last three reports.
Shenzhen New Industries Biomedical Engineering Co., Ltd. has completed 1 stock splits, with the recent split occurring on May 21, 2021.
The company's stock is traded on one exchange.

300832 Chart

People also search for

Aier Eye Hospital Group Co. Ltd.
¥ 9.07
+2.8345%
Haisco Pharmaceutical Group Co., Ltd.
¥ 70.28
-1.8436%
Shannon Semiconductor Tech Inc.
¥ 156.64
-1.2918%
Sichuan Kelun Pharmaceutical Co., Ltd.
¥ 46.41
+2.1347%
Hebei Changshan Biochemical Pharmaceutical Co., Ltd.
¥ 27.62
-1.7432%

Shenzhen New Industries Biomedical Engineering Co., Ltd. (300832) FAQ

What is the stock price today?

The current price is ¥49.02.

On which exchange is it traded?

Shenzhen New Industries Biomedical Engineering Co., Ltd. is listed on XSHE.

What is its stock symbol?

The ticker symbol is 300832.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 5.2%.

What is its market cap?

As of today, the market cap is 45.79B.

Has Shenzhen New Industries Biomedical Engineering Co., Ltd. ever had a stock split?

Shenzhen New Industries Biomedical Engineering Co., Ltd. had 1 splits and the recent split was on May 21, 2021.

Shenzhen New Industries Biomedical Engineering Co., Ltd. Profile

Biotechnology Industry
Healthcare Sector
Dr. Wei Rao CEO
XSHE Exchange
CNE100003T39 ISIN
CN Country
2,841 Employees
27 May 2026 Last Dividend
21 May 2021 Last Split
- IPO Date

Overview

Shenzhen New Industries Biomedical Engineering Co., Ltd. (NIBEC) is a pioneering force in the bio-medical field. Established in 1995, the company has cemented its reputation for innovation and quality in the healthcare sector. NIBEC specializes in the research, development, production, and sale of clinical laboratory instruments and in vitro diagnostic reagents. Catering to the needs of hospitals both within the People's Republic of China and on an international scale, NIBEC combines technological advancement with practical application, addressing the evolving demands of diagnostics and patient care. Headquartered in Shenzhen, one of China's leading technology hubs, NIBEC is at the forefront of the bio-medical industry, pushing the boundaries of what is possible in medical diagnostics and laboratory operations.

Products and Services

NIBEC offers a comprehensive range of products and services designed to enhance the efficiency and effectiveness of medical diagnostics and research. The company’s portfolio includes:

  • Immunoassay: NIBEC provides advanced immunoassay solutions that facilitate the qualitative and quantitative detection of molecules such as proteins, hormones, and antibodies in various biological samples. These solutions are critical for diagnosing a range of conditions and monitoring patient health.
  • Biochemistry/Electrolyte: The company’s biochemistry and electrolyte analysis systems offer precise measurement of biochemical parameters and electrolytes in body fluids, aiding in the diagnosis and treatment of diseases linked to metabolic and electrolyte imbalances.
  • Molecular Diagnostics: Emphasizing the detection and quantification of nucleic acids, NIBEC’s molecular diagnostic products enable rapid and accurate diagnosis of infectious diseases, genetic disorders, and cancer, facilitating personalized medicine and targeted therapies.
  • Point of Care Testing (POCT): POCT devices provided by NIBEC allow for immediate, bedside diagnostic testing, empowering clinicians with the timely information necessary for making critical decisions in patient care.
  • Lab Automation: NIBEC has developed lab automation systems that streamline operations, reduce manual errors, and increase the throughput of diagnostic tests. These systems are integral for high-volume laboratories seeking efficiency and consistency.
  • Integrated System: Providing holistic and integrated systems is at the core of NIBEC’s offerings. These encompass a seamless integration of hardware, software, and reagents to deliver a comprehensive solution for laboratory workflow optimization and patient data management.

Contact Information

Address: New Industry Biological Building, Shenzhen, China, 518118
Phone: 86 755 2650 1514